Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized phase 2/3 study of fluoropyrimidine and irinotecan plus bevacizumab versus trifluridine/tipiracil plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer

Next Previous
Trial Profile

A randomized phase 2/3 study of fluoropyrimidine and irinotecan plus bevacizumab versus trifluridine/tipiracil plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer

Status: Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 25 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Tipiracil/trifluridine (Primary) ; Fluorouracil; Gimeracil/oteracil/tegafur; Irinotecan; Levofolinic acid
  • Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
  • Focus Therapeutic Use
  • Acronyms TRUSTY
  • Sponsors Taiho Pharmaceutical

Most Recent Events

  • 09 Jan 2024 Results of exploratory biomarker analysis investigating the relationship between baseline plasma concentrations of angiogenesis-related factors and cell-free DNA (cfDNA), and the efficacy of FTD/TPI plus bevacizumab in patients with mCRC, published in the Targeted Oncology
  • 04 Mar 2023 Results published in the British Journal of Cancer
  • 22 Jan 2022 Results of post-hoc analysis assssing baseline tumor burden presented at the 2022 Gastrointestinal Cancers Symposium

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top